Skip to main content
Erschienen in: Supportive Care in Cancer 5/2013

01.05.2013 | Original Article

Evaluation of intrapsychic processes, anxiety, and depression in postmenopausal women affected by breast cancer: a case–control study

verfasst von: Anna Vespa, Marica Ottaviani, Massimo Rosselli, Simonetta Rossini, Lodovico Balducci

Erschienen in: Supportive Care in Cancer | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

Background

The study of intrapsychic modalities can help to understand the association between depression and breast cancer patients and what kind of intervention can be planned. There is evidence that breast cancer is associated with the development of depression. The study of intrapsychic modalities may explain this association. Therefore, we aimed at investigating the intrapsychic and interpersonal processes of the structure of personality, anxiety, and depression of postmenopause breast cancer women.

Methods

All participants (n = 63) underwent the following tests: SASB questionnaire (Structural Analysis of Interpersonal Behavior), describing intrapsychic and interpersonal processes, validated on the basis of DSMIV, and the CDQ and ASQ questionnaires describing depression and anxiety. We compared two groups: breast cancer (n = 63) and a healthy control group of women without cancer (n = 83).

Results

Patients with breast cancer presented medium to high levels of anxiety and depression and intrapsychic level showed that they had less autonomy in their choices with low acceptance of their own feelings and tendency to be depressed compared to the control group (Cl 1 autonomy F = 10.21, p < 0.05, Cl 2 autonomy and love F = 13.01, p < 0.001, Cl 3 love F = 10.50, p < 0.01, Cl 5 control F = 6.44, p < 0.05, Cl 6 control and hate F = 4.49, p < 0.05, ASQ F = 6.07, p < 0.05, and CDQ F = 6.24, p < 0.05).

Conclusions

Intrapsychic characteristics such as tendency to depression, inability to being in contact with their own feelings, may be linked to difficulties in facing treatment and their condition of illness. Knowledge of these modalities could allow to plan a psychotherapeutic and multidisciplinary intervention aimed at facing the different phases of medical treatment.
Literatur
1.
3.
Zurück zum Zitat Ollonen P, Lehtonen J, Eskelinen M (2005) Anxiety, depression, and the history of psychiatric symptoms in patients with breast disease: a prospective case–control study in Kuopio, Finland. Anticancer Res 25:2527–2534PubMed Ollonen P, Lehtonen J, Eskelinen M (2005) Anxiety, depression, and the history of psychiatric symptoms in patients with breast disease: a prospective case–control study in Kuopio, Finland. Anticancer Res 25:2527–2534PubMed
7.
Zurück zum Zitat Price MA, Tennant CC, Butow PN, Smith RC, Kennedy SJ, Kossoff MB, Dunn SM (2001) The role of psychosocial factors in the development of breast carcinoma: part II. Life event stressors, social support, defence style, and emotional control and their interaction. Cancer 15:686–697. doi:10.1002/1097-0142(20010215)91:4<686:AIDCNCR1052>3.0.CO;20CrossRef Price MA, Tennant CC, Butow PN, Smith RC, Kennedy SJ, Kossoff MB, Dunn SM (2001) The role of psychosocial factors in the development of breast carcinoma: part II. Life event stressors, social support, defence style, and emotional control and their interaction. Cancer 15:686–697. doi:10.1002/1097-0142(20010215)91:4<686:AIDCNCR1052>3.0.CO;20CrossRef
8.
Zurück zum Zitat Eskelinen M, Ollonen P (2009) Psychosocial risk scale (PRS)for breast cancer in patients with breast disease: a prospective case–control study in Kuopio, Finland. Anticancer Res 29:4765–4770PubMed Eskelinen M, Ollonen P (2009) Psychosocial risk scale (PRS)for breast cancer in patients with breast disease: a prospective case–control study in Kuopio, Finland. Anticancer Res 29:4765–4770PubMed
9.
Zurück zum Zitat Schraub S, Sancho-Garnier H, Velten M (2009) Should psychological events be considered cancer risk factors? Rev Epidemiol Sante Publique 57:113–123PubMedCrossRef Schraub S, Sancho-Garnier H, Velten M (2009) Should psychological events be considered cancer risk factors? Rev Epidemiol Sante Publique 57:113–123PubMedCrossRef
11.
Zurück zum Zitat Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D (2011) Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29:413–420. doi:10.1200/JCO.2010.28.4455 PubMedCrossRef Giese-Davis J, Collie K, Rancourt KM, Neri E, Kraemer HC, Spiegel D (2011) Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: a secondary analysis. J Clin Oncol 29:413–420. doi:10.​1200/​JCO.​2010.​28.​4455 PubMedCrossRef
13.
Zurück zum Zitat Michael YL, Perrin N, Bowen D, Cochrane BB, Wisdom JP, Brzyski R, Ritenbaugh C (2005) Expression and ambivalence over expression of negative emotion: psychometric analysis in the women's health initiative. J Women Aging 17:5–18. doi:10.1300/J074v17n01_02 PubMedCrossRef Michael YL, Perrin N, Bowen D, Cochrane BB, Wisdom JP, Brzyski R, Ritenbaugh C (2005) Expression and ambivalence over expression of negative emotion: psychometric analysis in the women's health initiative. J Women Aging 17:5–18. doi:10.​1300/​J074v17n01_​02 PubMedCrossRef
14.
Zurück zum Zitat Eskelinen M, Ollonen P (2010) The body image drawing analysis in women with breast disease and breast cancer; anxiety, colour and depression categories. Anticancer Res 30:683–691PubMed Eskelinen M, Ollonen P (2010) The body image drawing analysis in women with breast disease and breast cancer; anxiety, colour and depression categories. Anticancer Res 30:683–691PubMed
15.
Zurück zum Zitat Eskelinen M, Ollonen P (2011) Beck Depression Inventory (BDI) in patients with breast disease and breast cancer: a prospective case–control study. In Vivo 25:111–116PubMed Eskelinen M, Ollonen P (2011) Beck Depression Inventory (BDI) in patients with breast disease and breast cancer: a prospective case–control study. In Vivo 25:111–116PubMed
16.
Zurück zum Zitat Eskelinen M, Ollonen P (2011) MADRS in healthy study subjects, in patients with breast disease and breast cancer: a prospective case–control study. Anticancer Res 31:1065–1069PubMed Eskelinen M, Ollonen P (2011) MADRS in healthy study subjects, in patients with breast disease and breast cancer: a prospective case–control study. Anticancer Res 31:1065–1069PubMed
17.
Zurück zum Zitat Eskelinen M, Ollonen P (2011) Assessment of general anxiety in patients with breast disease and breast cancer using the STAI self evaluation test: a prospective case–control study in Finland. Anticancer Res 31:1801–1806PubMed Eskelinen M, Ollonen P (2011) Assessment of general anxiety in patients with breast disease and breast cancer using the STAI self evaluation test: a prospective case–control study in Finland. Anticancer Res 31:1801–1806PubMed
Metadaten
Titel
Evaluation of intrapsychic processes, anxiety, and depression in postmenopausal women affected by breast cancer: a case–control study
verfasst von
Anna Vespa
Marica Ottaviani
Massimo Rosselli
Simonetta Rossini
Lodovico Balducci
Publikationsdatum
01.05.2013
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 5/2013
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1659-5

Weitere Artikel der Ausgabe 5/2013

Supportive Care in Cancer 5/2013 Zur Ausgabe

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.